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1. Introduction 
More than 5 million people carry the diagnosis of heart failure in USA and almost 300,000 
people die of heart failure each year in USA1. Heart failure remains the most common 
discharge diagnosis for patients older than 65 years of age. In the Western world, most heart 
failure is related to coronary disease, and although the survival of patients post acute 
myocardial infarction has improved, this has resulted in an increase in the number of 
patients ultimately developing heart failure2. Advances in medical therapy have resulted in 
improved survival in patients with moderate and severe heart failure, but the prognosis for 
end-stage heart failure patients remains poor3-5. In patients with end-stage heart failure 
cardiac transplantation remains the gold standard of cardiac replacement therapy and it has 
shown the greatest survival benefit. However, the supply of donor hearts is limited. There is 
also an increase in the number of heart failure patients who are not candidates for cardiac 
transplantation, mainly due to older age and presence of co-morbidities. There has therefore 
been considerable interest in alternative forms of cardiac replacement therapy, either as a 
temporary bridge to transplantation or as a definitive destination strategy. Multiple 
different mechanical devices for long-term circulatory support have been developed, 
ranging from total artificial hearts to ventricular assist devices (VADs). The main purpose of 
a VAD is to unload the failing heart and help maintain forward cardiac output and vital 
organ perfusion. Originally introduced as a temporary bridge to recovery and then as a 
bridge to transplantation, VADs have evolved into permanent or “destination” therapy for a 
growing number of patients with refractory heart failure6. 
2. History and evolution of VADs 
Mechanical circulatory support is rapidly emerging as an adjunct/alternative to cardiac 
transplantation. Its development commenced at the National Institutes of Health in 1964 in 
USA with the initial focus on development of a total artificial heart, but, with few 
exceptions, this has had limited success7. The major attention has now shifted to mechanical 
ventricular assist devices. The first successful cardiac-assist device in humans was 
implanted by DeBakey at the Texas Heart Institute in 196678. Early devices were large and 
cumbersome with extracorporeal placement and provided temporary support only. The 
technological advancements led to the development of pulsatile LVAD design pioneered in 
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1976 as the Axio-symmetrical and Pierce-Donachy LVADs. A refined version of the latter 
device known as the Heartmate (Thoratec) was approved by the FDA as a bridging device 
to cardiac transplantation in 199478. Its updated version, the Heartmate XVE was approved 
as bridge therapy in 1998. The Randomized Evaluation of Mechanical Assistance in 
Treatment of Chronic Heart Failure (REMATCH) study evaluated the long term benefit of 
Heartmate XVE placement compared with optimal medical therapy in end-stage heart 
failure patients4. There was 48% reduction in death from all causes, attributable to LVAD 
therapy compared with best medical therapy in this trial. On this basis, the Heartmate XVE 
was approved for use as destination therapy in 2002. With time VADs have evolved 
significantly, with three major changes to date: (a) Transition from pulsatile to continuous-
flow devices; (b) Reduction in size with the preference for internal placement of the devices; 
(c) Use of electricity as a power source79. The newest continuous-flow VADs are much 
smaller in size and are silent in operation, leading to significantly greater patient 
satisfaction79. It makes this therapy more favourable for long-term support.  
3. Components of a VAD 
VADs support the failing heart by unloading the ventricle and generating flow to the 
systemic and/or pulmonary circulation. They can be used to support the left ventricle, right 
ventricle or both the ventricles. LVAD (Left Ventricular Assist Device) is the main assist 
device used in clinical practice. Use of isolated right ventricular assist device (RVAD) is a 
rare event80. It is usually inserted around the time of placement of a (LVAD) to provide 
biventricular assistance. Sometimes biventricular mechanical ventricular assist devices are 
also used primarily for cardiac support. In comparison to single chamber VAD, 
biventricular mechanical devices create a  complex system with two independent pumps, 
one right sided and the other left sided which supports both left and right ventricles. 
VAD typically has an inflow cannula, an outflow cannula, a pumping chamber, per-cutaneous 
driveline, a controller and power supply. VADs are usually implanted through a median 
sternotomy, typically during cardiopulmonary bypass80. The inflow cannula is connected to 
the heart and it decompresses the ventricular cavity and an outflow cannula returns blood 
to either the ascending aorta or the main pulmonary artery. The pumping chamber of the 
VAD is implanted sub-diaphragmatically to a pre-peritoneal or intra-abdominal position or 
may be situated in a para-corporeal position outside the body80. Smaller devices are being 
developed for thoracic implantation, some with outflow to the descending aorta. A 
percutaneous driveline, containing the control and power wires, is tunnelled through the 
skin of the abdominal wall. It connects the device to an external portable driver consisting of 
an electronic or pneumatic controller and a power supply that may be worn around the 
waist, carried in a shoulder bag, or contained within a small bedside monitor.  
Newer per-cutaneous VADs have a venous trans-septal inflow cannula that has a curved 
design at its end to facilitate ideal tip placement in the left atrium and contains a large end 
hole at its distal tip and 14 side holes to aspirate oxygenated blood from the left atrium. The 
cannula is attached to a continuous flow centrifugal blood pump, which in turn is driven by 
a 3-phase, brushless, direct current servomotor that is capable of delivering up to 5.0 L/min 
of blood flow. Blood is delivered from the pump to the femoral artery with an arterial 
perfusion catheter. This catheter ranges from 15F to17F and pumps blood from the left 
atrium to the right femoral artery. Alternatively, two 12F arterial perfusion catheters pump 
blood into the right and left femoral arteries. The pump is driven by an external 
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microprocessor- based controller. A pressure transducer monitors the infusion pressure and 
identifies any disruption in the infusion line. An in-line air bubble detector monitors for the 
presence of air in the infusion line. 
4. Types of VADs 
Many VADs are currently available commercially or in various stages of development. 
These were developed to satisfy special needs for either short or longer-term support  
and, therefore, differ markedly in their design characteristics, principles of operation, 
hemodynamic capabilities, method of insertion, and, importantly, durability. 
4.1 Percutaneous short-term devices 
Percutaneous short-term VADs include devices that are inserted through the femoral artery 
and advanced to the left ventricle. Examples of such percutaneous short-term VADs are 
Impella 2.5 pump and TandemHeart. Impella 2.5 pump (Abiomed Inc., Danvers, MA) is an 
impeller-driven, axial flow pump, capable of pumping 2.5 L/min.13 TandemHeart 
(CardiacAssist, Inc., Pittsburgh, PA) is a low speed centrifugal continuous-flow pump that 
drains oxygenated blood through a catheter advanced across the interatrial septum to the 
left atrium and pumps it back to one or both femoral arteries.14 The experience with these 
devices is increasing, particularly with the Impella pump.15,16  
4.2 Longer-term assist devices 
The currently available longer-term VADs are categorized into three generations, reflecting 
the order in which they were developed and the type of pumping mechanism they use.  
4.3 First-generation VADs 
These are pulsatile devices that use pusher plates and have inflow and outflow valves. 
These devices are efficacious at unloading the left ventricle and maintaining the circulation, 
with the capacity to pump up to 10 L/min79. Examples of such devices are the HeartMate® I 
or XVE (Thoratec Corp., Pleasanton, CA) and the Novacor VAD (WorldHeart Inc., Oakland, 
California, USA)81. These implantable VADs are placed intra-abdominally or pre-peritoneally 
in a pocket under the abdominal rectus muscle and connected to the apex of the left 
ventricle and to the ascending aorta81. There is increased risk of hematomas and infections 
as they are large in volume, requiring extensive surgical dissection81. The percutaneous 
leads of these devices, especially those of the HeartMate XVE, are large and stiff and contain 
an air vent channel, which makes the system quite noisy and uncomfortable. All pulsatile 
devices have biological or mechanical valves to allow a unidirectional blood flow. 
Anticoagulation is necessary for all devices, except the HeartMate XVE. The latter has a 
textured inner surface of the pump stimulating formation of a biological layer preventing 
thrombus formation. Only aspirin is given as antithrombotic prophylaxis81.  
Outcomes of first-generation devices 
After the REMATCH study, Heartmate XVE was approved for use as “destination therapy” 
(DT) in 2002. Although the VAD therapy group had significantly greater survival and 
quality of life at both one and two years of follow-up, the survival at two years was only 
28%. In addition, there were large numbers of readmissions and device-related 
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complications including sepsis and stroke. Therefore, use of Heartmate XVE as destination 
has not been widely accepted. 
The first generation devices are also used successfully as a “bridge to transplantation” (BTT) 
with a perioperative mortality of 15–20% and an overall survival until device explantation of  
60–70%81. However, in the majority of studies, the maximal support duration does not 
exceed 6 months, and in most studies mean support duration ranges only from 50 to 60 
days.17-19 Results in experienced high volume centers (>10 implants per year) tend to be 
better than in low-volume centers. Survival and quality of life has been closely related to 
adverse events such as bleeding, infections, thrombo-embolic events and technical failures. 
Thrombo-embolic events resulting in transient ischemic attacks or even stroke is a 
devastating complication. In literature, there is a high variability in rates ranging from 5 to 
50%, depending on the different LVAD types and variation in anticoagulation protocols81.  
4.4 Second generation VADs 
There is a need of more reliable and smaller devices due to growing waiting lists and long 
waiting times for heart transplantation. Second generation VADs can answer this need with 
smaller size and longer durability in comparison to first generation devices. The most 
common second generation VADs are the HeartMate 2 VAD (Thoratec Inc.), the Jarvik 2000 
(Jarvik Heart Inc., New York, New York), Micromed Debakey VAD and the Berlin Heart 
Incor (Berlin Heart AG). They have the continuous flow impeller pumps which are 
considerably smaller and safer to insert. Because they have only one moving part (the rotor), 
they are expected to be more durable than first-generation devices. To maintain an 
international normalized ratio (INR) of 2.0–2.5, the use of these pumps requires full 
anticoagulant therapy coupled with antiplatelet medications, such as aspirin or clopidogrel. 
The HeartMate 2 is the most successful second-generation device with over 2500 implants 
worldwide. It is one-seventh of the size and one-fourth the weight of the HeartMate XVE81.  
Outcomes of second-generation devices 
Heartmate II device has been approved by the US FDA for implantation as BTT in April 
2008 and as DT in January 2010. The mean duration of support reported from the use of 
these continuous flow, rotary pumps is considerably longer compared with the first-
generation devices (166–236 vs. 50–60 days). Two studies have shown 2 years survival of 65 
and 69% with no mechanical failure and low fatal adverse event rates. The incidence of 
thrombo-embolic events in HeartMate 2 patients is in most studies comparable with those 
seen with Heart- Mate XVE, however the risk of hemorrhagic stroke rates tend to be higher 
(2–3%), probably as a result of the anticoagulation81. 
4.5 Third generation VADs 
Third-generation VADs are small centrifugal pumps in which the rotor is magnetically or 
mechanically suspended and, therefore, does not use ball bearings. Drivelines are less thick 
and more flexible. These features, coupled with the lower number of revolutions per minute, 
should enhance durability in comparison with the second generation pumps. Examples of 
such third generation VADs are the VentrAssist VAD (Ventracor Ltd, Chatswood, New 
South Wales, Australia)20 and the DuraHeart (Terumo, Somerset, New Jersey, USA).21 
Outcomes of third-generation devices 
These devices are thought to last as long as 5–10 years, and their performance is being 
evaluated in several phase I studies involving the HVAD® (Heart- Ware, Miramar, FL) 
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devices, and more recently the DuraHeart® (Terumo Kabushiki Kaisha, Tokyo, Japan) 
system. They still carry the risk of neurological complications like stroke as well as risk of 
infections. 
5. Clinical indications for VADs 
Mechanical devices can be used for a wide spectrum of diseases based on the therapeutic 
goals of circulatory support as well as the duration of treatment. They can be used for short 
term as well long term duration. The indications are typically divided into 3 categories: 
bridge to recovery, bridge to transplantation, and destination therapy.  
5.1 Bridge to recovery 
VADs as a “Bridge to recovery” are used for patients who need only temporary support for 
days to weeks in anticipation of recovery of ventricular function followed by weaning and 
removal of device. This includes patients with acute inflammatory cardiomyopathies, acute 
cardiogenic or post-cardiotomy shock and myocardial infarction. The ability of LVADs to 
support an acutely failing heart while it recovers function is well documented.16,17,33 There 
are observations regarding the potential for myocardial recovery even in patients with 
chronic heart failure. 
Various studies have documented that the unloaded left ventricle undergoes a process of 
reverse remodeling, as categorized by multiple different indices e.g. decrease in left 
ventricular size34 and normalization of pressure–volume relationship curves.35 Cellular 
structure and function also improves and reverts back toward normal.36-39 Thus, the 
reduction in left ventricular volumes is not just a function of the unloading provided by the 
VAD but actually reflects alterations in the dynamics of myocyte function.  
5.2 Molecular changes in myocardium after VAD implantation 
A reduction in myocardial contractility is one of the most important causes of dysfunction in 
heart failure.25 Both the electrical and mechanical components of the process of excitation-
contraction (E-C) coupling are altered, and Ca2+ handling is clearly a target for therapy in 
heart failure.25 VAD therapy strongly affects E-C coupling. After VAD treatment, 
cardiomyocyte contractility is increased26,27 and the force-frequency relationship is 
normalized.28,29 Action-potential duration is reduced,30,31 mirroring the shortening of the QT 
interval on electrocardiogram in patients after prolonged support.32 In addition to E-C 
coupling mechanisms, several other molecular mechanisms responsible for VAD-induced 
reverse remodeling have been described. These include effects at the levels of metabolic 
pathways, immune and inflammatory responses, transcription factors, the adrenergic 
system, cytoskeletal proteins, the extracellular matrix, neurohormonal activation, and 
apoptosis and necrosis signaling, a breadth that suggests profound reverse remodeling at 
the molecular level. Clinically these changes improve left ventricular function and patients 
have a dramatic increase in their exercise capacity following LVAD implantation.44-46 These 
findings encouraged the explantation of LVADs in select patients who have demonstrated 
sufficient recovery of myocardial function. To date clinical results are mixed and although 
the large number of studies report regression or normalization of the pathological substrate 
following VAD treatment, the clinical evidence for recovery remains limited. To date, an 
average of only 5%–10% of patients who undergo mechanical circulatory support 
demonstrate adequate recovery of ventricular function to allow device explantation.33,34 
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There is also concern that prolonged mechanical unloading reduces cardiac cell function, as 
well as cell size, in a time-dependent manner35-40 which may lead to myocardial atrophy. 
Unloading induced atrophy can be an important impediment to myocardial recovery and 
removal of the VADs for bridge-to-recovery, limiting the efficacy of VAD treatment.41 
Minimizing unloading-induced atrophy may be an important strategy to obtain the 
beneficial effects of VADs and, to this end, a pharmacological regimen that includes 
clenbuterol has been tested in combination with VAD treatment. Clenbuterol is a unique β2 
adrenoceptor agonist that is currently approved only for patients with asthma, but has been 
shown in animal models to lead to significant hypertrophy of skeletal and cardiac muscle 
and enhanced mechanical strength of contraction.42 A novel combination regimen including 
the use of five oral medications known to provide various degrees of reverse remodeling, 
plus clenbuterol, was used in patients with non-ischemic cardiomyopathy who were 
transplant candidates and required a VAD for refractory heart failure.43 In nearly 70% of 
patients on the combination therapy, the VAD could be removed within one year. After four 
years of follow-up, the average ejection fraction had improved from 15% preoperatively to 
62%. These encouraging data have prompted the initiation of the Harefield Recovery 
Protocol Study (HARPS). The trial will not only assess clinical cardiac recovery but also 
explore molecular mechanisms of clenbuterol. 
5.3 Bridge to transplantation 
“Bridge-to-transplantation” is the strategy in which VADs are used for improving 
ventricular function and peripheral perfusion in patients awaiting cardiac transplantation. 
Several studies have demonstrated that VADs ensure sustained improvement in 
hemodynamic status and quality of life in patients awaiting cardiac transplantation.9 More 
than 80% of VAD-treated patients undergoing cardiac transplantation have a normal or 
improved post-transplant outcome.10 
When implanted in patients refractory to medical therapy, LVADs lead to improved end 
organ function as well as overall physical conditioning.10,11 LVAD markedly decreases the 
filling pressures and increases cardiac output by taking over the work of the left ventricle, 
the. This leads to lower pulmonary vascular resistance and a reduction in afterload for the 
right ventricle. Additionally, the increase in cardiac output provides additional preload for 
the right ventricle, which further enhances its function. This improvement in right 
ventricular function and mechanical replacement of left ventricular output by LVAD results 
in more efficient delivery of oxygen to end-organ tissues. As a result, the presence of the 
LVAD can partially or totally reverse functional impairment of these organs. This is most 
clearly evident in the kidneys, in which renal failure can improve or resolve following the 
implantation of an LVAD. All organ systems benefit from the increase in perfusion, 
allowing sick patients to stabilize or improve as they wait for a heart transplant. In addition 
to providing an increased length of time on the organ waiting list, LVADs significantly 
improve outcomes by reducing patients’ comorbidities at the time of transplant. This makes 
them better transplant candidates and improves their posttransplant outcomes.12,13 
The following criteria should generally be met prior to consideration of LVAD implant: 
clinical evidence of impaired end-organ perfusion with cardiac index <2 L/min/m2, 
pulmonary capillary wedge pressure >20 mmHg, and systolic blood pressure <80 mmHg 
despite maximal medical support, including inotropes and an intraaortic balloon pump, if 
indicated.20 Although it is important to meet these criteria, LVAD implantation should be 
performed before extensive end-organ damage for maximal chance of success.21 
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5.4 Destination therapy 
“Destination Therapy” is perhaps the most exciting strategy in which VADs are used as an 
alternative to cardiac transplant to support the patients for their entire life. It involves the 
largest population of the patients with end stage heart failure who are unable to receive 
cardiac transplantation. The success of LVAD implantation as “Bridge to transplantation” 
(BTT) in candidates with refractory heart failure led to the investigations for its use as an 
alternative to Heart transplantation HT. The first DT feasibility trials were designed over 15 
years ago. The REMATCH trial was one of the most remarkable endeavours in the history of 
VADs that assessed the feasibility of LADs for Destination Therapy (DT). The trial was 
conducted between May 1998 and July 2001 at 20 US hospitals. REMATCH trial showed 
significant improvement of the quality of life in patients supported with LVAD and improved one-
year survival from 25% to 52%.4 These data led to the US Food and Drug Administration (FDA) 
approval of the modified HeartMate XVE LVAD for use as DT in November 2002, thus launching a 
new era of surgical therapy for advanced heart failure. One of the more recent trials the 
Heartmate II trial was conducted between March 2005 and May 2007 and it has shown that 
patients supported with HM II VAD (continuous flow VAD) had significantly improved 
two-year survival when compared to HM XVE recipients (58% vs. 24%, respectively) and 
significantly improved probability of freedom from stroke and device failure at two years, 
as compared to the recipients of pulsatile devices. These data led to approval of Heartmate 
II VAD for DT by US FDA in January 2010. 
5.5 Indications for DT
82
 
The criteria for VAD implantation for DT are based largely on the entry criteria into the 
REMATCH trial. They are:  
1. Class IV NYHA symptoms for at least 60 of the last 90 days despite maximized oral 
therapy, including dietary salt restriction, diuretics, digitalis, beta-blockers, and 
angiotensin converting enzyme (ACE) inhibitors (if tolerated), or requirement of 
inotropic support as outlined by the AHA/ACC guidelines for heart failure treatment 
2. LVEF of ≤25%,  
3. Peak oxygen consumption of <12 mL/kg/min or documented inability to wean 
intravenous inotropic therapy owing to symptomatic hypotension, decreasing renal 
function, or worsening pulmonary congestion 
4. Contraindication to HT due to either age greater than 65 years or comorbidities such as 
insulin-dependent diabetes mellitus with end-organ damage, chronic renal failure, or 
others, and  
5. Appropriate body size (≥1.5 m2) to support the HM XVE LVAD implantation.  
5.6 Survival with DT 
As mentioned earlier the results of the REMATCH trial revealed significant improvement in one-year 
survival from 25% to 52%.with improvement of the quality of life in patients supported with VAD in 
comparison with optical medical therapy. In the post rematch era despite improvements in design, 
there was no significant improvement in clinical outcomes with pulsatile flow devices. Recently 
published Heart Mate II trial showed that patients supported with continuous flow HM II LVAD had 
significantly improved two-year survival when compared to pulsatile flow HM XVE recipients (58% 
vs. 24%, respectively) and significantly improved probability of freedom from stroke and device 
failure at two years, as compared to the recipients of pulsatile devices.  
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Experiences of the post-REMATCH era have shown that many DT recipients who were 
initially deemed not transplantable have improved their condition and became eligible for 
HT; 1 in every 5 recipients of HM XVE in the post-REMATCH era (17% of the 280 studied 
patients) underwent successful HT within 10 months from device implant. In most of these 
cases the improvements occurred due to the resolution of deemed irreversible pulmonary 
hypertension, recovery of renal function, weight loss, achieving cancer-free period, or 
reversal of other conditions. Therefore, one should not assume that DT would in the future 
preclude transplantation. Although LVAD implantation in the post-REMATCH era 
continues to be associated with substantial survival benefit as compared to medical therapy 
the outcomes of DT remain substantially inferior to those of HT (85% one-year survival). 
6. Risk stratification and patient selection 
Data from the REMATCH study4 and the more recent post-REMATCH Registry,8 of 300 
recipients of the pulsatile HeartMate XVE device implanted as destination therapy since the 
close of REMATCH, as well as the HeartMate II trial22 with the continuous flow pump in 
patients awaiting heart transplant, have all demonstrated that nearly 70% of the deaths in 
the first year occurred prior to hospital discharge. This finding is clearly independent of the 
pump design or indication for its use and reflects the very high severity of illness of these 
patients at the time of device implantation.23 
The risk factors associated with death prior to hospital discharge were analyzed using data 
from the post-REMATCH Registry of destination therapy patients.24 Those identified by 
multivariate analysis included platelets <149,000, prolonged coagulation (INR > 1.2), low 
pulmonary artery pressure (reflective of right ventricular failure), and importantly, 
malnutrition as evidenced by the crude marker of serum albumin <3.3 mg/dl. Hazard ratio 
was calculated for each of these preoperative laboratory variables, converted that hazard to 
a numerical score for each variable, and sum of these scores into a total risk score for in-
hospital mortality was calculated. The data showed a tight linear correlation between higher 
risk score and increased in-hospital mortality, with high sensitivity and specificity. When 
the lowest-risk and medium risk cohorts were combined, the average survival was 70% at 
one year. For those with the highest risk score, the in-hospital mortality was >80% and a 
one-year survival was only 6%.  
Many risk factors may be mitigated by intensive medical therapy; nutrition, coagulation 
profiles, right ventricular function, and renal function can be improved. Risk scoring can be 
used to select the optimal timing for device implantation. A patient with a very high or 
prohibitive risk score might undergo intensive medical management for a week, resulting in 
significant improvement in the risk score and a better outcome. These findings are based on 
the first generation of pulsatile pumps for destination therapy, but similar predictive 
accuracy has been recently reported in a large cohort of bridge-to-transplantation patients 
supported with both pulsatile and continuous-flow pumps.24 If validated, the use of 
preoperative risk scoring will likely lead to improved outcomes with VADs. 
7. Complications  
Some of the most common perioperative complications of VAD placement include 
hemorrhage, right ventricular failure, sepsis, air embolism, and kinking of conduits. The late 
complications are mechanical device failure, neurologic events, and infection.4,44,45 
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7.1 Mechanical failure  
Mechanical failure of VADs is an important cause of morbidity and mortality in patients 
living with VADs, because of the prolonged support required for both bridge to 
transplantation and destination therapy. The REMATCH trial has shown that 35% of 
patients experienced component failure within 24 months of implantation.4 Another study 
on 109 patients with pulsatile VADs found that the probability of device failure was 6%, 
12%, 27%, and 64% at 6 months, 1 year, 18 months, and 2 years, respectively.46 On the other 
hand for continuous flow pumps the mechanical durability seems to be markedly improved. 
In one study on patients with a HeartMate II VAD as bridge to transplantation, only 5 of 133 
(4%) developed either device thrombosis or a complication from surgical implantation 
necessitating device replacement.  
Complications can arise in any component from the portable drive/system controller that 
controls and powers the device to the inflow and outflow cannulae, valves, batteries, and 
the VAD itself. These devices have system controllers and monitors that provide visual and 
auditory alarms during malfunction. To diagnose suspected device malfunction these alarms 
must be used in conjunction with clinical, laboratory, and imaging data. For troubleshooting, 
systematic catheter-, angiography-, fluoroscopy-, and echocardiography-based protocols 
have been developed to help diagnose common malfunctions.47-50 If necessary, repair of a 
dysfunctional VAD or removal and replacement with a new VAD may be performed. 
7.2 Neurologic events 
Implanted mechanical devices are susceptible to thrombo-embolic events due to their 
unique properties. The foreign surfaces of VADs can activate the immune system, platelets, 
and the coagulation cascade. In addition, the blood-contact surfaces of VADs along with 
turbulent blood flow increase the risk of shear stress on blood and thrombi formation.51 The 
unmasking or inadequate treatment of hypertension, older age, higher VAD flow and index, 
and inadequate anticoagulation further increase the risk for development of neurological 
events. Neurologic complications from VAD therapy include cerebro-vascular accidents and 
transient ischemic attacks, with an incidence ranging from 0.009 to 5.73 events per patient-
year.51,52 The prevalence of neurologic events with destination therapy has ranged from 44% 
in the REMATCH trial (HeartMate XVE) to 57% in the European LionHeart Clinical Utility 
Baseline Study. Intracranial hemorrhage, syncope, seizure, brain abscesses, and 
encephalopathy have all been reported. These data are mostly from the bridge-to-
transplantation experience and may not apply to destination therapy patients who are 
generally older and have more co-morbidities and longer implantation periods.53  
Not all devices have the same neurologic event rate. Design modifications like the use of 
novel biologic materials, textured coatings, and a single moving part, are believed to reduce 
the risk of thrombus formation. Promising data from the HeartMate II trial demonstrated 
reduced adverse events per patient year with respect to stroke (0.19 vs. 0.44) and non-stroke 
(0.26 vs. 0.67) neurologic events compared with a pulsatile flow pump8. Appropriate device 
selection, prevention of infection that can activate platelets, blood pressure control, and 
meticulous regulation of anticoagulation are all critical for the prevention of cerebro-
vascular accidents after VAD implantation.54,55 
7.3 Infection 
VAD infections occur most frequently between 2 weeks and 2 months after implantation56. 
The predominant organisms are Gram-positive organisms Staphylococcus epidermidis and 
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Staphylococcus aureus followed by enterococci.57-59 Other commonly implicated organisms 
include Gram negative bacilli such as Pseudomonas aeruginosa, Enterobacter, and Klebsiella 
species, along with fungi.58,60 Frequent use of broad-spectrum antibiotics, particularly 
during the index hospitalization, is believed to increase susceptibility for fungal infections, 
which are associated with the highest risk of death.60,61  
The most common site of infection is the percutaneous driveline, which can often be 
managed successfully with wound care and antibiotics.62 However, a driveline infection can 
spread to other components of the VAD resulting in bacteremia, sepsis, and endocarditis63. 
Sepsis in patients with mechanical assist devices has been reported to be the leading cause 
of death and can result in cerebral emboli and multi-organ failure.58,60 Other infections, 
including mediastinitis and peritonitis, have also been reported. 
Many strategies have been adopted to try to minimize device-related and wound infections. 
Proper care of the driveline exit site must be maintained. Strict aseptic technique (e.g., sterile 
gloves, mask) must be followed when caring for the percutaneous exit site. The site should 
be gently cleaned with a mild antimicrobial soap and rinsed with sterile normal saline after 
which a dry sterile dressing should be applied. At all times, the driveline must be secured to 
minimize the risk of trauma; immobilization can be performed with an abdominal binder, 
additional gauze, tape, or a stoma-adhesive device.64,65 There are also many modifications 
made to device design to further decrease the risk of infection which include the use of 
larger single-lead drivelines and drivelines coated with chlorhexidine and silver 
sulfadiazine.60,66 Studies of rotary blood pumps with their reduced surface area for 
colonization and smaller surgical pump pocket suggest that they are less prone to 
infection.67,68  
8. Future directions 
The combination of VADs with adjunctive therapies may result in further improvement in 
ventricular function and lead to higher rates of clinical recovery. VADs provides an ideal 
platform to apply adjunctive therapies that directly target the causes of disease and 
potentially lead to myocardial regeneration and full restoration of function.69 An adjunctive 
therapy that is best evaluated in patients with mechanical circulatory support is stem cell 
therapy. The clinical trials of cell therapy performed so far using autologous adult 
progenitor cells in acute myocardial infarction patients70 have shown limited efficacy, with 
little information on the mechanisms responsible for the small functional improvement 
observed.71 There is only less than 2% survival of transplanted cells in animals models 
present after two weeks post-transplant, and true cardiomyogenesis does not seem to 
occur.72 From this it appears that paracrine mechanisms are most likely to account for the 
improvements in functional recovery of the recipient myocardium.73 Other cell types, such 
as embryonic stem cells, inducible pluripotent stem cells, and cardiac progenitor cells, have 
larger potential for cardiac regeneration but their integration in the recipient myocardium 
remains a crucial problem.74 Cell delivery is usually given either by intracoronary or by 
peripheral intravenous injection, with only a few patients undergoing direct delivery into 
the wall of the cardiac ventricle.75 Having the heart directly exposed at the time of the VAD 
implant as a bridge-to-transplantation allows the direct intracardiac injection of a large 
number of cells into very specific mapped areas of the ventricle and provides an 
opportunity to study the direct effects at the histological and molecular levels when the 
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heart is explanted for recovery or at time of transplant. In addition, the more favorable 
milieu offered by the VAD induced reverse remodeling, together with the reduced 
ventricular pressures, may promote the survival and integration of the injected cells, which 
would otherwise succumb in the hostile environment of the failing myocardium.  
Gene therapy is also tried as an adjunctive therapy with VAD insertion, to manipulate 
critical genes differentially regulated in advanced heart failure76,77. Gene transfer can be 
achieved either by using viral vectors or by transfection into the patient’s progenitor/ stem 
cells to be used for cell therapy, prior to VAD surgery. Gene therapy could directly target 
mechanisms responsible for heart failure, aim to enhance angiogenesis or myogenesis and 
protect the transplanted cells from apoptosis, and prevent the unloading-induced negative 
remodeling.  
9. Conclusion 
Though cardiac transplantation remains the gold standard for cardiac replacement therapy, 
as donor hearts are a very limited resource, alternatives in the form of mechanical assist 
devices have become a useful solution in treating patients with end stage heart failure. The 
field of VAD therapy is clearly expanding, being used as bridge to transplantation and as 
destination therapy. The new generation of continuous-flow pumps has yielded 
encouraging preliminary data suggesting both improved outcomes and device durability. 
The development of validated risk stratification models will lead to improved patient 
selection and timing of device implant, with overall improved outcomes over time. The 
novel adjunctive therapies like the stem cell transplant and the gene therapy may well usher 
in a new era of enhanced utilization of these devices for truly sustainable ventricular 
recovery as an alternative to life-long support. 
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